DE112006002617T5 - Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite - Google Patents
Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite Download PDFInfo
- Publication number
- DE112006002617T5 DE112006002617T5 DE112006002617T DE112006002617T DE112006002617T5 DE 112006002617 T5 DE112006002617 T5 DE 112006002617T5 DE 112006002617 T DE112006002617 T DE 112006002617T DE 112006002617 T DE112006002617 T DE 112006002617T DE 112006002617 T5 DE112006002617 T5 DE 112006002617T5
- Authority
- DE
- Germany
- Prior art keywords
- shell
- core
- polymer
- component
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011258 core-shell material Substances 0.000 title claims abstract description 387
- 238000000034 method Methods 0.000 title claims abstract description 151
- 239000002131 composite material Substances 0.000 title claims abstract description 63
- 230000008569 process Effects 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 13
- 229920000642 polymer Polymers 0.000 claims abstract description 561
- 239000008358 core component Substances 0.000 claims abstract description 161
- 239000000306 component Substances 0.000 claims abstract description 115
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 87
- 238000004132 cross linking Methods 0.000 claims abstract description 65
- 239000007791 liquid phase Substances 0.000 claims abstract description 61
- 239000012071 phase Substances 0.000 claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 239000002245 particle Substances 0.000 claims description 279
- 230000027455 binding Effects 0.000 claims description 231
- 239000000203 mixture Substances 0.000 claims description 180
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 112
- 239000011591 potassium Substances 0.000 claims description 111
- 229910052700 potassium Inorganic materials 0.000 claims description 110
- 125000000623 heterocyclic group Chemical group 0.000 claims description 61
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 60
- 239000000543 intermediate Substances 0.000 claims description 60
- 150000001412 amines Chemical class 0.000 claims description 50
- 239000007864 aqueous solution Substances 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 230000003252 repetitive effect Effects 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- -1 benzoxadiazolyl Chemical group 0.000 claims description 40
- 208000002682 Hyperkalemia Diseases 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 229920001577 copolymer Polymers 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 35
- 229920002554 vinyl polymer Polymers 0.000 claims description 35
- 239000008346 aqueous phase Substances 0.000 claims description 32
- 229920006037 cross link polymer Polymers 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 29
- 125000003277 amino group Chemical group 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 238000005341 cation exchange Methods 0.000 claims description 17
- 230000003993 interaction Effects 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 14
- 239000002168 alkylating agent Substances 0.000 claims description 10
- 229940100198 alkylating agent Drugs 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 9
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 230000009021 linear effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 5
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000011257 shell material Substances 0.000 description 389
- 239000011162 core material Substances 0.000 description 145
- 150000001768 cations Chemical class 0.000 description 128
- 238000003556 assay Methods 0.000 description 126
- 239000011734 sodium Substances 0.000 description 123
- 150000002500 ions Chemical class 0.000 description 93
- 239000000178 monomer Substances 0.000 description 92
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 90
- 229910001414 potassium ion Inorganic materials 0.000 description 76
- 210000001035 gastrointestinal tract Anatomy 0.000 description 62
- 239000000243 solution Substances 0.000 description 54
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 53
- 239000011324 bead Substances 0.000 description 52
- 239000011777 magnesium Substances 0.000 description 48
- 229910052708 sodium Inorganic materials 0.000 description 48
- 229910001425 magnesium ion Inorganic materials 0.000 description 44
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 42
- 229910001415 sodium ion Inorganic materials 0.000 description 40
- 230000035699 permeability Effects 0.000 description 39
- 210000001072 colon Anatomy 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 238000000576 coating method Methods 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 32
- 229910001424 calcium ion Inorganic materials 0.000 description 32
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 31
- 239000011248 coating agent Substances 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 28
- 239000002609 medium Substances 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 27
- 239000001257 hydrogen Substances 0.000 description 27
- 230000002209 hydrophobic effect Effects 0.000 description 26
- 238000013459 approach Methods 0.000 description 24
- 239000011575 calcium Substances 0.000 description 24
- 229910052749 magnesium Inorganic materials 0.000 description 24
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 23
- 235000001055 magnesium Nutrition 0.000 description 23
- 229940091250 magnesium supplement Drugs 0.000 description 23
- 239000002253 acid Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 239000012528 membrane Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 238000000099 in vitro assay Methods 0.000 description 19
- 238000005804 alkylation reaction Methods 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 238000006116 polymerization reaction Methods 0.000 description 18
- 229920002873 Polyethylenimine Polymers 0.000 description 17
- 230000029142 excretion Effects 0.000 description 17
- 210000003608 fece Anatomy 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 210000000813 small intestine Anatomy 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- 239000004971 Cross linker Substances 0.000 description 16
- 230000029936 alkylation Effects 0.000 description 16
- 238000011065 in-situ storage Methods 0.000 description 16
- 229960002796 polystyrene sulfonate Drugs 0.000 description 16
- 239000011970 polystyrene sulfonate Substances 0.000 description 16
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 15
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 15
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 230000002860 competitive effect Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical group NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 14
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 239000003729 cation exchange resin Substances 0.000 description 13
- XWJBRBSPAODJER-UHFFFAOYSA-N 1,7-octadiene Chemical compound C=CCCCCC=C XWJBRBSPAODJER-UHFFFAOYSA-N 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000007910 chewable tablet Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 230000002085 persistent effect Effects 0.000 description 11
- 229920000867 polyelectrolyte Polymers 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 230000002688 persistence Effects 0.000 description 10
- 230000004962 physiological condition Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 125000000547 substituted alkyl group Chemical group 0.000 description 10
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 9
- 125000002091 cationic group Chemical group 0.000 description 9
- 239000007771 core particle Substances 0.000 description 9
- 230000018044 dehydration Effects 0.000 description 9
- 238000006297 dehydration reaction Methods 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 229920001519 homopolymer Polymers 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- TYCFGHUTYSLISP-UHFFFAOYSA-N 2-fluoroprop-2-enoic acid Chemical compound OC(=O)C(F)=C TYCFGHUTYSLISP-UHFFFAOYSA-N 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000005354 coacervation Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 150000004820 halides Chemical class 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000003999 initiator Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000001878 scanning electron micrograph Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- MWZJGRDWJVHRDV-UHFFFAOYSA-N 1,4-bis(ethenoxy)butane Chemical compound C=COCCCCOC=C MWZJGRDWJVHRDV-UHFFFAOYSA-N 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 229910052796 boron Inorganic materials 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 150000001767 cationic compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 150000002118 epoxides Chemical class 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 210000003405 ileum Anatomy 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229910001411 inorganic cation Inorganic materials 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 239000012948 isocyanate Chemical class 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- JAYXSROKFZAHRQ-UHFFFAOYSA-N n,n-bis(oxiran-2-ylmethyl)aniline Chemical compound C1OC1CN(C=1C=CC=CC=1)CC1CO1 JAYXSROKFZAHRQ-UHFFFAOYSA-N 0.000 description 6
- VJHGSLHHMIELQD-UHFFFAOYSA-N nona-1,8-diene Chemical compound C=CCCCCCC=C VJHGSLHHMIELQD-UHFFFAOYSA-N 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 229920000768 polyamine Polymers 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- OZDGMOYKSFPLSE-UHFFFAOYSA-N 2-Methylaziridine Chemical compound CC1CN1 OZDGMOYKSFPLSE-UHFFFAOYSA-N 0.000 description 5
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 229940068682 chewable tablet Drugs 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 210000004921 distal colon Anatomy 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000010526 radical polymerization reaction Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- LTMQZVLXCLQPCT-UHFFFAOYSA-N 1,1,6-trimethyltetralin Chemical compound C1CCC(C)(C)C=2C1=CC(C)=CC=2 LTMQZVLXCLQPCT-UHFFFAOYSA-N 0.000 description 4
- MIIIXQJBDGSIKL-UHFFFAOYSA-N 2-morpholin-4-ylethanesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)CCN1CCOCC1 MIIIXQJBDGSIKL-UHFFFAOYSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000013038 Hypocalcemia Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 238000010533 azeotropic distillation Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940023913 cation exchange resins Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 125000000743 hydrocarbylene group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 230000000705 hypocalcaemia Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910001410 inorganic ion Inorganic materials 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 4
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- JUVWKFKXIVLAHQ-UPHRSURJSA-N (z)-2,3-difluorobut-2-enedioic acid Chemical compound OC(=O)C(\F)=C(\F)C(O)=O JUVWKFKXIVLAHQ-UPHRSURJSA-N 0.000 description 3
- SOBDFTUDYRPGJY-UHFFFAOYSA-N 1,3-bis(ethenylsulfonyl)propan-2-ol Chemical compound C=CS(=O)(=O)CC(O)CS(=O)(=O)C=C SOBDFTUDYRPGJY-UHFFFAOYSA-N 0.000 description 3
- QWZOJDWOQYTACD-UHFFFAOYSA-N 2-ethenylsulfonyl-n-[2-[(2-ethenylsulfonylacetyl)amino]ethyl]acetamide Chemical compound C=CS(=O)(=O)CC(=O)NCCNC(=O)CS(=O)(=O)C=C QWZOJDWOQYTACD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- 239000004593 Epoxy Chemical group 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000029422 Hypernatremia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000005210 alkyl ammonium group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- NLDGJRWPPOSWLC-UHFFFAOYSA-N deca-1,9-diene Chemical compound C=CCCCCCCC=C NLDGJRWPPOSWLC-UHFFFAOYSA-N 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000004815 dispersion polymer Substances 0.000 description 3
- 238000012674 dispersion polymerization Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- IQIJRJNHZYUQSD-UHFFFAOYSA-N ethenyl(phenyl)diazene Chemical compound C=CN=NC1=CC=CC=C1 IQIJRJNHZYUQSD-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- GEAWFZNTIFJMHR-UHFFFAOYSA-N hepta-1,6-diene Chemical compound C=CCCCC=C GEAWFZNTIFJMHR-UHFFFAOYSA-N 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000010871 livestock manure Substances 0.000 description 3
- 238000010550 living polymerization reaction Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000006855 networking Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229920005604 random copolymer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- MLMGJTAJUDSUKA-UHFFFAOYSA-N 2-ethenyl-1h-imidazole Chemical class C=CC1=NC=CN1 MLMGJTAJUDSUKA-UHFFFAOYSA-N 0.000 description 2
- LSSICPJTIPBTDD-UHFFFAOYSA-N 2-ethenyl-1h-indole Chemical class C1=CC=C2NC(C=C)=CC2=C1 LSSICPJTIPBTDD-UHFFFAOYSA-N 0.000 description 2
- RDAFNSMYPSHCBK-UHFFFAOYSA-N 3-phenylprop-2-en-1-amine Chemical compound NCC=CC1=CC=CC=C1 RDAFNSMYPSHCBK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000012639 Balance disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020944 Hypoaldosteronism Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 238000012695 Interfacial polymerization Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 150000003926 acrylamides Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 229920001002 functional polymer Polymers 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000013529 heat transfer fluid Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
- YQCFXPARMSSRRK-UHFFFAOYSA-N n-[6-(prop-2-enoylamino)hexyl]prop-2-enamide Chemical compound C=CC(=O)NCCCCCCNC(=O)C=C YQCFXPARMSSRRK-UHFFFAOYSA-N 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229920001289 polyvinyl ether Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003134 recirculating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 238000010557 suspension polymerization reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 125000002348 vinylic group Chemical group 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- BCAGFJXMCZSAHD-UHFFFAOYSA-N 1,2-bis(2-iodoethoxy)ethane Chemical compound ICCOCCOCCI BCAGFJXMCZSAHD-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- WEERVPDNCOGWJF-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene Chemical compound C=CC1=CC=C(C=C)C=C1 WEERVPDNCOGWJF-UHFFFAOYSA-N 0.000 description 1
- LGJCFVYMIJLQJO-UHFFFAOYSA-N 1-dodecylperoxydodecane Chemical compound CCCCCCCCCCCCOOCCCCCCCCCCCC LGJCFVYMIJLQJO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- MCXLQFOCWZMFHV-UHFFFAOYSA-N 4-ethenyl-2h-triazole Chemical class C=CC1=CNN=N1 MCXLQFOCWZMFHV-UHFFFAOYSA-N 0.000 description 1
- YPIINMAYDTYYSQ-UHFFFAOYSA-N 5-ethenyl-1h-pyrazole Chemical class C=CC=1C=CNN=1 YPIINMAYDTYYSQ-UHFFFAOYSA-N 0.000 description 1
- VTQMJCSAHXYXPJ-UHFFFAOYSA-N 5-ethenyl-2h-tetrazole Chemical class C=CC1=NN=NN1 VTQMJCSAHXYXPJ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101710141544 Allatotropin-related peptide Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010069571 Atrioventricular dissociation Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LCFVJGUPQDGYKZ-UHFFFAOYSA-N Bisphenol A diglycidyl ether Chemical compound C=1C=C(OCC2OC2)C=CC=1C(C)(C)C(C=C1)=CC=C1OCC1CO1 LCFVJGUPQDGYKZ-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical class O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000104547 Ziziphus oenoplia Species 0.000 description 1
- 235000005505 Ziziphus oenoplia Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical group 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006047 digesta Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical class OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 description 1
- PNIDWTQLQYNPNE-UHFFFAOYSA-N ethenyl sulfamate Chemical compound NS(=O)(=O)OC=C PNIDWTQLQYNPNE-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000013335 mesoporous material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical class OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229940061584 phosphoramidic acid Drugs 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000001420 photoelectron spectroscopy Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000012769 potassium ion homeostasis Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007152 ring opening metathesis polymerisation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000012756 sodium ion homeostasis Effects 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007155 step growth polymerization reaction Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000009283 thermal hydrolysis Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000014122 turkey meat Nutrition 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72305505P | 2005-09-30 | 2005-09-30 | |
| US60/723,055 | 2005-09-30 | ||
| PCT/US2006/038900 WO2007038802A2 (en) | 2005-09-30 | 2006-10-02 | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE112006002617T5 true DE112006002617T5 (de) | 2008-08-28 |
Family
ID=37600828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE112006002617T Withdrawn DE112006002617T5 (de) | 2005-09-30 | 2006-10-02 | Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8586097B2 (https=) |
| EP (1) | EP1928433A2 (https=) |
| JP (2) | JP2009510233A (https=) |
| KR (1) | KR20080057319A (https=) |
| CN (1) | CN101321519A (https=) |
| AU (1) | AU2006294455B2 (https=) |
| BR (1) | BRPI0616603A2 (https=) |
| CA (1) | CA2624112A1 (https=) |
| DE (1) | DE112006002617T5 (https=) |
| GB (1) | GB2446076B (https=) |
| WO (1) | WO2007038802A2 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509365B8 (pt) * | 2004-03-30 | 2021-05-25 | Ilypsa Inc | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
| US8877250B2 (en) | 2005-12-20 | 2014-11-04 | Bridgestone Corporation | Hollow nano-particles and method thereof |
| US8337824B2 (en) * | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| AU2013204879B2 (en) * | 2008-08-22 | 2015-10-29 | Vifor (International) Ltd. | Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
| US20100111892A1 (en) * | 2008-08-22 | 2010-05-06 | Relypsa, Inc. | Crosslinked polyfluoroacrylic acid and processes for the preparation thereof |
| PT2365988E (pt) * | 2008-08-22 | 2015-10-22 | Relypsa Inc | Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia |
| WO2010022381A1 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| WO2010078320A2 (en) * | 2008-12-31 | 2010-07-08 | Bridgestone Corporation | Core-first nanoparticle formation process, nanoparticle, and composition |
| US9062144B2 (en) | 2009-04-03 | 2015-06-23 | Bridgestone Corporation | Hairy polymeric nanoparticles with first and second shell block polymer arms |
| US9115222B2 (en) | 2009-12-29 | 2015-08-25 | Bridgestone Corporation | Well defined, highly crosslinked nanoparticles and method for making same |
| US9314523B2 (en) * | 2010-09-21 | 2016-04-19 | Elwha Llc | Ingestible salt grabber |
| SI2673237T2 (sl) | 2011-02-11 | 2025-12-31 | Zs Pharma, Inc | Uporaba cirkonijevega silikata v zdravljenju hiperkalemije |
| ES2895909T3 (es) | 2011-06-27 | 2022-02-23 | Vifor Pharma Tech Ltd | Procedimiento para la conversión de un éster polimérico a un ácido polimérico |
| US10128534B2 (en) * | 2011-09-02 | 2018-11-13 | Seeo, Inc. | Microsphere composite electrolyte |
| US9428604B1 (en) | 2011-12-30 | 2016-08-30 | Bridgestone Corporation | Nanoparticle fillers and methods of mixing into elastomers |
| US20130244234A1 (en) * | 2012-01-23 | 2013-09-19 | Glc Biotechnology, Inc. | Stool collection methods for analysis of dna in stool |
| US9943637B2 (en) | 2012-06-11 | 2018-04-17 | ZS Pharma, Inc. | Microporous zirconium silicate and its method of production |
| CN104968336A (zh) * | 2012-07-11 | 2015-10-07 | Zs制药公司 | 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物 |
| EP2812091B1 (en) | 2012-09-17 | 2021-03-10 | W.R. Grace & CO. - CONN. | Chromatography media and devices |
| EP2811983B1 (en) | 2012-09-17 | 2019-05-01 | W.R. Grace & CO. - CONN. | Functionalized particulate support material and methods of making and using the same |
| KR20210005314A (ko) | 2012-10-08 | 2021-01-13 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
| CN104797263B (zh) | 2012-10-22 | 2018-02-09 | Zs制药公司 | 用于治疗高钾血症的微孔硅酸锆 |
| US10695365B2 (en) | 2012-10-22 | 2020-06-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
| US9724279B2 (en) * | 2012-10-26 | 2017-08-08 | Syneurx International Corp. | Core-shell particles, preparation process thereof, and composition containing the same |
| EP3003327B1 (en) * | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| US9655862B2 (en) * | 2013-10-29 | 2017-05-23 | Shaker A. Mousa | Ocular nanoformulation and method of use in angiogenesis-mediated disorders |
| US9572831B2 (en) * | 2013-10-29 | 2017-02-21 | Shaker A. Mousa | Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis |
| US9480703B2 (en) * | 2013-10-29 | 2016-11-01 | Shaker A. Mousa | Method and composition of glycosaminoglycans in sickle cell and vascular disorders |
| GB2534775B (en) * | 2013-12-26 | 2020-12-09 | Halliburton Energy Services Inc | Fluid loss additive for water based drilling fluids with improved thermal stability |
| ES2887110T3 (es) | 2014-01-16 | 2021-12-21 | Grace W R & Co | Medios para cromatografía de afinidad y dispositivos para cromatografía |
| PL3137209T3 (pl) | 2014-05-02 | 2023-01-02 | W.R. Grace & Co. - Conn. | Funkcjonalizowany materiał nośnikowy i sposoby wytwarzania oraz stosowania funkcjonalizowanego materiału nośnikowego |
| US10940109B2 (en) | 2014-08-27 | 2021-03-09 | The Regents Of The University Of Colorado | Multilayer polymeric matrix based medical devices |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| KR102566292B1 (ko) | 2015-06-05 | 2023-08-10 | 더블유.알. 그레이스 앤드 캄파니-콘. | 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법 |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| US9592253B1 (en) | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
| JP6443302B2 (ja) * | 2015-10-30 | 2018-12-26 | コニカミノルタ株式会社 | 多孔性樹脂粒子の製造方法 |
| JP2017176907A (ja) * | 2016-03-28 | 2017-10-05 | 株式会社日本カプセルプロダクツ | マイクロカプセルの製造方法及びこの製造方法で製造されたマイクロカプセル |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| US10840502B2 (en) | 2017-02-24 | 2020-11-17 | Global Graphene Group, Inc. | Polymer binder for lithium battery and method of manufacturing |
| US11978904B2 (en) | 2017-02-24 | 2024-05-07 | Honeycomb Battery Company | Polymer binder for lithium battery and method of manufacturing |
| US10985373B2 (en) | 2017-02-27 | 2021-04-20 | Global Graphene Group, Inc. | Lithium battery cathode and method of manufacturing |
| US11742475B2 (en) | 2017-04-03 | 2023-08-29 | Global Graphene Group, Inc. | Encapsulated anode active material particles, lithium secondary batteries containing same, and method of manufacturing |
| US10483533B2 (en) | 2017-04-10 | 2019-11-19 | Global Graphene Group, Inc. | Encapsulated cathode active material particles, lithium secondary batteries containing same, and method of manufacturing |
| US10862129B2 (en) | 2017-04-12 | 2020-12-08 | Global Graphene Group, Inc. | Lithium anode-protecting polymer layer for a lithium metal secondary battery and manufacturing method |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| US11043694B2 (en) | 2018-04-16 | 2021-06-22 | Global Graphene Group, Inc. | Alkali metal-selenium secondary battery containing a cathode of encapsulated selenium particles |
| US11121398B2 (en) | 2018-06-15 | 2021-09-14 | Global Graphene Group, Inc. | Alkali metal-sulfur secondary battery containing cathode material particulates |
| US10978744B2 (en) | 2018-06-18 | 2021-04-13 | Global Graphene Group, Inc. | Method of protecting anode of a lithium-sulfur battery |
| US12218346B2 (en) | 2018-06-21 | 2025-02-04 | Honeycomb Battery Company | Method of extending cycle-life of a lithium metal secondary battery |
| US11043662B2 (en) | 2018-08-22 | 2021-06-22 | Global Graphene Group, Inc. | Electrochemically stable elastomer-encapsulated particles of cathode active materials for lithium batteries |
| US11239460B2 (en) * | 2018-08-22 | 2022-02-01 | Global Graphene Group, Inc. | Method of producing electrochemically stable elastomer-encapsulated particles of cathode active materials for lithium batteries |
| US11223049B2 (en) * | 2018-08-24 | 2022-01-11 | Global Graphene Group, Inc. | Method of producing protected particles of cathode active materials for lithium batteries |
| US12444744B2 (en) | 2018-10-15 | 2025-10-14 | Honeycomb Battery Company | Electrochemically stable anode particulates for lithium secondary batteries |
| US10971724B2 (en) | 2018-10-15 | 2021-04-06 | Global Graphene Group, Inc. | Method of producing electrochemically stable anode particulates for lithium secondary batteries |
| US10971725B2 (en) | 2019-01-24 | 2021-04-06 | Global Graphene Group, Inc. | Lithium metal secondary battery containing elastic polymer foam as an anode-protecting layer |
| CN112480884B (zh) * | 2020-12-08 | 2022-07-05 | 中国石油天然气股份有限公司 | 一种壳膜结构堵漏材料、制备方法及使用方法 |
| EP4401712A4 (en) * | 2021-09-14 | 2025-08-27 | Nulixir Inc | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MANUFACTURE THEREOF |
| CN113877546B (zh) * | 2021-09-27 | 2023-11-24 | 汕头大学 | 一种壳聚糖基高效亚硝酸盐生物吸附剂及其制备方法 |
| CN116178796B (zh) * | 2023-02-27 | 2025-02-11 | 山东高速路用新材料技术有限公司 | 一种包覆型硫化剂、沥青稳定剂及其制备方法和应用 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427794A (en) | 1980-08-22 | 1984-01-24 | Bayer Aktiengesellschaft | Process for the preparation of bead polymers of uniform particle size by polymerization of microencapsulated monomer |
| US4675140A (en) | 1984-05-18 | 1987-06-23 | Washington University Technology Associates | Method for coating particles or liquid droplets |
| EP0373852A2 (en) | 1988-12-13 | 1990-06-20 | Smith Kline & French Laboratories Limited | Compounds |
| EP0415214A2 (de) | 1989-09-01 | 1991-03-06 | Bayer Ag | Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten |
| US5112993A (en) | 1989-11-14 | 1992-05-12 | E. I. Du Pont De Nemours And Company | Process for the preparation of difluoromaleic anhydride |
| US5374422A (en) | 1989-07-19 | 1994-12-20 | Lowchol Scientific, Inc. | Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol |
| US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5718920A (en) | 1993-11-25 | 1998-02-17 | Salternate B.V. | Particles for binding monovalent cations |
| WO2001002452A1 (en) | 1999-07-02 | 2001-01-11 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto |
| US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
| US6475510B1 (en) | 1997-12-19 | 2002-11-05 | Smithkline Beecham Corporation | Process for manufacturing bite-dispersion tablets |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2611730A (en) | 1950-09-02 | 1952-09-23 | Simth Kline & French Lab | Medical preparation for reducing the body level of sodium |
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US3499960A (en) * | 1965-01-25 | 1970-03-10 | Merck & Co Inc | Palatable coated particles of an anion exchange resin |
| FR2171934B1 (https=) | 1972-02-16 | 1974-09-13 | Rhone Poulenc Sa | |
| US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
| US4143130A (en) | 1977-08-29 | 1979-03-06 | Warren-Teed Laboratories, Inc. | Method for treating kidney stones |
| US4470975A (en) | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
| US4380590A (en) | 1978-09-19 | 1983-04-19 | Rohm And Haas Company | Emulsion copolymer cation exchange resins |
| US4362711A (en) | 1980-07-11 | 1982-12-07 | Evreka Inc. | Blood cholesterol level reducing agent and method |
| DE3149136A1 (de) | 1981-12-11 | 1983-06-23 | Robert Bosch Gmbh, 7000 Stuttgart | Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen |
| JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| US4587888A (en) * | 1984-02-09 | 1986-05-13 | Allied Corporation | Extensible piston with breakable or displaceable coupler |
| US4747881A (en) | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US5186937A (en) | 1985-06-07 | 1993-02-16 | A.E.C. Societe De Chimie Organique Et Biologique | Composition for feeding ruminants |
| IT1190349B (it) | 1986-06-16 | 1988-02-16 | Prodotti Formenti Srl | Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle |
| JPS63218713A (ja) | 1987-02-17 | 1988-09-12 | Daikin Ind Ltd | α−フルオロアクリル酸系重合体ならびに用途 |
| US4837015A (en) | 1987-03-05 | 1989-06-06 | Carolina Medical Products Company, Inc. | Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels |
| FR2634377B1 (fr) | 1988-06-30 | 1991-09-27 | Cortial | Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif |
| GB8817015D0 (en) | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
| US5091175A (en) | 1990-05-14 | 1992-02-25 | Erbamont Inc. | Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane |
| DE69016014T2 (de) | 1990-07-04 | 1995-08-31 | Marcin Krotkiewski | Blutdrucksenkendes Präparat. |
| IE914179A1 (en) | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
| US5162110A (en) | 1990-12-19 | 1992-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Binding theophylline to ion exchange resins |
| US5281631A (en) | 1991-12-20 | 1994-01-25 | Arch Development Corp. | Phosphonic acid based ion exchange resins |
| ATE168707T1 (de) | 1992-08-20 | 1998-08-15 | Du Pont | Vernetzte polymerische ammoniumsalze |
| US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
| AU6818894A (en) | 1993-05-20 | 1994-12-20 | Geltex Pharmaceuticals, Inc. | Process for adjusting ion concentration in a patient and compositions therefor |
| US5618530A (en) | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US5824339A (en) | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
| JP3885130B2 (ja) | 1996-06-11 | 2007-02-21 | 株式会社大塚製薬工場 | グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤 |
| CA2258744A1 (en) | 1996-06-27 | 1997-12-31 | G.D. Searle And Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| US5935599A (en) | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
| JPH10130154A (ja) | 1996-10-29 | 1998-05-19 | Otsuka Pharmaceut Factory Inc | 腎疾患患者用延命率改善薬 |
| KR100440544B1 (ko) | 1998-07-31 | 2004-07-15 | 니켄 가가쿠 가부시키가이샤 | 양이온 교환수지 제제 |
| EP1140037A1 (en) | 1999-01-07 | 2001-10-10 | ELAN CORPORATION, Plc | Multiparticulate oral dosage forms |
| US6558665B1 (en) | 1999-05-18 | 2003-05-06 | Arch Development Corporation | Encapsulating particles with coatings that conform to size and shape of the particles |
| US20020054903A1 (en) | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| CA2396915A1 (en) | 2000-01-14 | 2001-07-19 | Otsuka Pharmaceutical Factory, Inc. | Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same |
| FR2812632B1 (fr) | 2000-08-07 | 2003-03-07 | Solvay | Procede pour la synthese de composes fluoroorganiques |
| AU2002232955A1 (en) | 2000-11-20 | 2002-05-27 | Dow Global Technologies Inc. | In vivo use of water absorbent polymers |
| AU2002242103A1 (en) | 2001-02-06 | 2002-08-19 | Ash Medical Systems, Inc. | Monovalent-selective cation exchangers as oral sorbent therapy |
| US7033639B2 (en) | 2001-05-16 | 2006-04-25 | Rohm And Haas Company | Polyaniline coating composition |
| US6881484B2 (en) | 2001-05-30 | 2005-04-19 | Mitsubishi Kagaku Iatron, Inc. | Core-shell particle including signal-generating substance enclosed therein and process for producing the same |
| JP2004149525A (ja) | 2002-10-09 | 2004-05-27 | Sekisui Chem Co Ltd | カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤 |
| CA2516457C (en) | 2003-02-25 | 2011-12-06 | Finnfeeds Finland Oy | A simulated moving bed system and process |
| JP4526008B2 (ja) * | 2003-07-24 | 2010-08-18 | 秀樹 山本 | ポリビニルアルコール系粒状ゲル及びその製造方法 |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| CA2551528A1 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| BRPI0509365B8 (pt) * | 2004-03-30 | 2021-05-25 | Ilypsa Inc | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
-
2006
- 2006-10-02 BR BRPI0616603-2A patent/BRPI0616603A2/pt not_active IP Right Cessation
- 2006-10-02 CN CNA2006800442852A patent/CN101321519A/zh active Pending
- 2006-10-02 GB GB0806894A patent/GB2446076B/en not_active Expired - Fee Related
- 2006-10-02 AU AU2006294455A patent/AU2006294455B2/en not_active Ceased
- 2006-10-02 EP EP06816275A patent/EP1928433A2/en not_active Withdrawn
- 2006-10-02 US US12/088,611 patent/US8586097B2/en not_active Expired - Fee Related
- 2006-10-02 WO PCT/US2006/038900 patent/WO2007038802A2/en not_active Ceased
- 2006-10-02 DE DE112006002617T patent/DE112006002617T5/de not_active Withdrawn
- 2006-10-02 KR KR1020087010230A patent/KR20080057319A/ko not_active Ceased
- 2006-10-02 JP JP2008533794A patent/JP2009510233A/ja active Pending
- 2006-10-02 CA CA002624112A patent/CA2624112A1/en not_active Abandoned
-
2012
- 2012-06-19 JP JP2012137940A patent/JP2012176992A/ja active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427794A (en) | 1980-08-22 | 1984-01-24 | Bayer Aktiengesellschaft | Process for the preparation of bead polymers of uniform particle size by polymerization of microencapsulated monomer |
| US4675140A (en) | 1984-05-18 | 1987-06-23 | Washington University Technology Associates | Method for coating particles or liquid droplets |
| EP0373852A2 (en) | 1988-12-13 | 1990-06-20 | Smith Kline & French Laboratories Limited | Compounds |
| US5374422A (en) | 1989-07-19 | 1994-12-20 | Lowchol Scientific, Inc. | Ingestible [hydrophobic] polymeric amines useful for lowering blood cholesterol |
| EP0415214A2 (de) | 1989-09-01 | 1991-03-06 | Bayer Ag | Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten |
| US5112993A (en) | 1989-11-14 | 1992-05-12 | E. I. Du Pont De Nemours And Company | Process for the preparation of difluoromaleic anhydride |
| US5718920A (en) | 1993-11-25 | 1998-02-17 | Salternate B.V. | Particles for binding monovalent cations |
| US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US6475510B1 (en) | 1997-12-19 | 2002-11-05 | Smithkline Beecham Corporation | Process for manufacturing bite-dispersion tablets |
| US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
| WO2001002452A1 (en) | 1999-07-02 | 2001-01-11 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto |
Non-Patent Citations (44)
| Title |
|---|
| Agarwal, R. et al. (1994) Gastroenterology 107: 548-571 |
| Agarwal, R., R. Afzalpurkar, et al. (1994), "Pathophysiology of potassium absorption and secretion by the human intestine." Gastroenterology 107(2): 548-71 |
| Agarwal, R., R. et al., "Pathophysiology of potassium absorption and secretion by the human intestine." Gastroenterology 107(2): 548-71 (1994) |
| Angeln-Nielsen K. et al., Resonium A-induced hypocalcaemic tetany. Dan Med Bull. Sep; 30(5): 348-9 (1983) |
| Benoit J. P. et al., J. Microencapsulation, 2003, 20(1) 87-128 |
| Berlyne, G. M. et al., Cation exchange resins in hyperkalaemic renal failure, Isr J Med Sci, 3: 45-52 (1967) |
| Bogachev et al., Zhurnal Organisheskoi Khimii, 1986, 22(12), 2578-83 |
| Chen, L. et al., Macromolecules (1998), 31(3), 787-794 |
| Evans, B. M. et al., Ion-exchange resins in the treatment of anuria, Lancet, 265: 791-5 (1953) |
| Figuly et al., Macromolecules, 1997, 30, 6174-6184 |
| Gassen et al., J Fluorine Chemistry, 55, (1991) 149-162, KF Pittman, C. U. |
| Hazell, T (1985) World Rev Nutr Diet 46:1-123 |
| Hunt, C. D. et al., "Aluminum, boron, calcium, copper, iron, magnesium, manganese, molybdenum, phosphorus, potassium, sodium, and zinc: concentrations in common Western foods and estimated daily intakes by infants; toddlers; and male and female adolescents, adults, and seniors in the United States." J. Am. Diet Assoc. 101(9): 1058-60 (2001) |
| Hunt, CD und Meacham, SL (2001) J Am Diet Assoc 101: 1058-1060 |
| Ichekawa H et al., International Journal of Pharmaceuticals, 216 (2001), 67-76 |
| Ito et al., Macromolecule, (1992), 25, 7313-7316 |
| Kaneko et al., Macromolecular Rapid Communications (2003) 24(13), 789-792 |
| Kraft et al., Langmuir, 2003, 19, 910-915 |
| Krajewska, B., Reactive and Functional polymers 47, 2001, 37-47 |
| Leach, K. et al., J. Microencapsulation, 1999, 16(2), 153-167 |
| M. Ueda, et al. (1980) Macromolecules 13(5): 1031-1036 |
| Mandal, A. K. 1997, Hypokalemia and hyperkalemia, Med Clin North Am. 81: 611-39 |
| Mandal, AK (1997) Med Clin North Am 81: 611-639 |
| McCarthy, J. et al., "Divalent Cation Metabolism: Calcium", in Atlas of Diseases of the Kidney. Band 1. R. W. Schrier, Hrsg, Blackwell Sciences, Philadelphia (1999) |
| McCarthy, J. et al., "Divalent Cation Metabolism: Magnesi<?page 27?>um", in Atlas of Diseases of the Kidney. Band 1. R. W. Schrier, Hrsg., Blackwell Sciences, Philadelphia (1999) |
| McChesney, E. W., Effects of long-term feeding of sulfonic ion exchange resin an the growth and mineral metabolism of rats, Am J Physiol 177: 395-400 (1954) |
| Ng YY et al., Reduction of serum calcium by sodium sulfonated polystyrene resin, J. Formos Med Assoc. May; 89(5): 399-402 (1990) |
| Nightingale E. R., J. Phys. Chem., 63, (1959), 1381-89 |
| Remington: TheScience and Practice of Pharmacy, von A. R. Gennaro (Hrsg.), 20. Auflage, 2000 |
| Ross, E. J. et al. "Observations an cation exchange resins in the small and large intestines." Clin. Sci. (Lond) 13(4): 555-66 (1954) |
| Salas-Coll, C. A., J. C. Kermode, et al. (1976), "Potassium transport across the distal colon in man." Clin. Sci. Mol. Med. 51(3): 287-96 |
| Salas-Colt, C. A. et al., "Potassium transport across the distal colon in man.", Clin. Sci. Mol. Med., 51(3): 287-96 (1976) |
| Sata et al., Die Angewandte Makromolekulare Chemie 171, (1989), 101-117 (Nr. 2794) |
| Sata et al., J. Membrane Science, 206 (2002), 31-60 |
| Schwartz, MV (1987) Am J Nurs 87: 1292-1299 |
| Shiga, A., T. et al., "Correlations among pH and Mg, Ca, P, Na, K, Cl- and HCO3- contents of digesta in the gastrointestinal tract of rats." Nippon Juigaku Zasshi 49(6): 973-9 (1987) |
| Spencer, A. G. et al., "Cation exchange in the gastrointestinal tract." Br. Med. J. 4862: 603-6 (1954) |
| Spencer, A. G. et al., Cation exchange in the gastrointestinal tract. Br. Med J. 4862: 603-6 (1954) |
| Stover H. et al., Macromolecules, 1999, 32, 2838-2844 |
| W. Jost, Diffusion in Solids, Liquids and Gases, Acad. Press, New York, 1960 |
| Wrong, O. A. et al., "In Vivo Dialysis of Faeces as a Method of Stool Analysis. I. Technique and Results in Normal Subjects." Clin. Sci. 28: 357-75 (1965) |
| Wrong, O. M. (1971), "Rote of the human colon in Homeostasis." Scientific Basis of Medicine: 192-215 |
| Wrong, O. M., "Role of the human colon in Homeostasis." Scientific Basis of Medicine: 192-215 (1971) |
| Wrong, O., A. Metcalfe-Gibson, et al. (1965), "In Vivo Dialysis of Faeces as a Method of Stool Analysis. I. Technique and Results in Normal Subjects." Clin. Sci. 28: 357-75 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624112A1 (en) | 2007-04-05 |
| BRPI0616603A2 (pt) | 2012-12-25 |
| JP2012176992A (ja) | 2012-09-13 |
| KR20080057319A (ko) | 2008-06-24 |
| US20090186093A1 (en) | 2009-07-23 |
| GB2446076A (en) | 2008-07-30 |
| WO2007038802A2 (en) | 2007-04-05 |
| AU2006294455B2 (en) | 2013-06-20 |
| EP1928433A2 (en) | 2008-06-11 |
| GB0806894D0 (en) | 2008-05-21 |
| JP2009510233A (ja) | 2009-03-12 |
| US8586097B2 (en) | 2013-11-19 |
| WO2007038802A3 (en) | 2007-10-11 |
| AU2006294455A1 (en) | 2007-04-05 |
| CN101321519A (zh) | 2008-12-10 |
| GB2446076B (en) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE112006002617T5 (de) | Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite | |
| DE112005000730B4 (de) | Ionen bindende Polymere und ihre Verwendung | |
| US10905711B2 (en) | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal | |
| US7488495B2 (en) | Ion binding polymers and uses thereof | |
| WO2007038801A2 (en) | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof | |
| EP3219312B1 (en) | Ion binding polymers and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: RELYPSA, INC., SANTA CLARA, CALIF., US |
|
| R005 | Application deemed withdrawn due to failure to request examination |
Effective date: 20131003 |